IgG4-Related Disease
New IgG4-related disease research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), phase 3 trial results and real-world studies added momentum to steroid-sparing flare prevention. In the same months, relapse risk, organ damage, and biopsy-based diagnosis stayed central in the evidence. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Flare-prevention antibodies. Phase 3 results moved from early hints to clearer flare reduction signals.
- Steroid-sparing options. Targeted oral and alternative immunosuppressants entered clinical reports.
- Relapse patterns. Relapse management shifted toward post-relapse escalation and timing signals.
- Tracking activity. Single lab values gave way to trend- and imaging-based signals.
- Biopsy for clarity. More tools were proposed, but tissue confirmation stayed central.
New
September 2026
- Relapse prevention trial. A blinded add-on drug trial finished enrollment and is being analyzed.
- Tofacitinib reports. In a small series, most people improved on tofacitinib.
- Rituximab response marker. A lower IgG4-to-total IgG ratio over time matched better response.
- Cancer-like imaging. Blood tests and scans sometimes helped, but biopsy was often needed.
August 2026
- Repeat relapse care. Steroids plus other immune medicines were linked to fewer repeat relapses.
- B cell antibodies. An expert review centered on B cell antibodies and ongoing maintenance treatment.
- Disease activity signs. Very high IgG4 and a breath test rose with higher activity.
- Cancer look-alikes. Using scans, blood tests, and biopsy together reduced cancer mix-ups.
July 2026
- BTK pill study. In a small study, some stayed flare-free without steroids.
- Stent removal timing. Earlier steroids were linked to later ureter stent removal.
- Biopsy for clarity. Biopsy helped when scans looked like cancer or inflammation.
- IgG4 can be normal. Blood IgG4 was sometimes normal despite biopsy-proven disease.
June 2026
- Fewer flares. Obexelimab lowered flares and reduced steroid rescue over one year.
- Safety follow-up. Real-world studies are tracking inebilizumab safety over time.
- Tissue confirmation. Biopsy results often clarified unclear scans or blood tests.
- Cancer-like masses. Mass-like findings sometimes needed repeat or larger biopsies.
May 2026
- CCL19 blood marker. In one study, blood CCL19 levels tended to rise with active IgG4-related disease and fall during remission.
- PET/CT activity and relapse timing. Higher activity on a specialized whole-body PET/CT scan was linked to a shorter time to relapse.
- Biopsy when scans look like cancer. When imaging looked cancer-like, biopsy often helped distinguish IgG4-related inflammation from cancer or other conditions.
- Relapse builds over years. In long-term follow-up of type 1 autoimmune pancreatitis, relapses continued to accumulate over time.
April 2026
- Early organ damage. In one longer follow-up study, organ damage was often present early and became more common over time.
- Relapse linked to damage. In the same report, people with relapsing disease tended to have more lasting damage by the last follow-up visit.
- Diagnosis can mimic cancer. IgG4-related disease often resembled cancer, lymphoma, or other immune diseases, so diagnosis could be difficult.
- Early blood-pattern research. An early lab study found B-cell metabolic patterns that separated IgG4-related disease samples from controls, but this is not yet proven for routine use.
March 2026
- Fewer flares with B‑cell therapy. A B‑cell–depleting treatment was linked to fewer disease flares.
- More people off steroids. Rituximab was linked to more people being off steroids.
- PET/CT clarifies organ involvement. Whole‑body PET/CT often helped confirm the diagnosis and map which organs were involved.
- PET activity score (early evidence). A proposed PET‑based activity score separated active from inactive disease, but it is not yet well validated.
February 2026
- Relapse risk: trends vs one value. In one cohort, a single IgG4 blood level did not predict relapse, but an IgG4 change-over-time measure did.
- Azathioprine maintenance outcomes. In a small group, azathioprine after steroid treatment was followed by long remissions for many, but relapses and side effects (including infections and lab abnormalities) were still reported.
- Biopsy clarifies confusing scans. Across organs, imaging often looked like cancer or infection until a tissue biopsy confirmed IgG4-related disease, and one mimic was explained by VEXAS syndrome found on genetic testing.
- No single activity marker fits all. Immune cell and cytokine patterns tracked with disease activity in some cohorts, but results varied, and plasmablast levels did not consistently match scans or symptom-based activity in one group.
January 2026
- B-cell antibodies. B-cell antibodies were used after steroid relapse for longer control.
- Pericardium surgery. Pericardiectomy improved constrictive pericarditis when medicines did not.
- Relapse risk factors. Relapse was more common with multi-organ disease or high IgG.
- Bile-duct criteria. New bile-duct criteria found more cases while separating key cancers.
Get the monthly update by email
Subscribe here to receive an email when a new monthly IgG4-related disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).